
Arrowhead Pharmaceuticals, Inc.
ARWRAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
| Date | Firm | Analyst | Target | Price Then | Source |
|---|---|---|---|---|---|
| Oct 15, 2026 | UBS | Joon Lee | $109.00(+87%) | $58.37 | TheFly |
| Sep 24, 2026 | Goldman Sachs | Andrea Newkirk | $74.00(+11%) | $66.96 | TheFly |
| Aug 31, 2026 | RBC Capital | Luca Issi | $100.00(+21%) | $82.32 | StreetInsider |
| Aug 6, 2026 | H.C. Wainwright | $120.00(+40%) | $85.61 | TheFly | |
| Aug 5, 2026 | Stifel Nicolaus | $104.00(+16%) | $89.59 | TheFly | |
| Jul 27, 2026 | H.C. Wainwright | $115.00(+34%) | $85.60 | TheFly | |
| Jul 23, 2026 | Morgan Stanley | $120.00(+36%) | $88.38 | TheFly | |
| Jul 23, 2026 | Piper Sandler | Edward Tenthoff | $126.00(+42%) | $88.70 | TheFly |
| Jul 22, 2026 | Chardan Capital | Keay Nakae | $115.00(+26%) | $91.03 | TheFly |
| Jul 13, 2026 | Stifel Nicolaus | James Condulis | $98.00(+32%) | $74.11 | TheFly |
| May 13, 2026 | Bernstein | $46.00(-42%) | $79.04 | TheFly | |
| May 8, 2026 | Chardan Capital | $90.00(+15%) | $77.95 | TheFly | |
| Apr 21, 2026 | Morgan Stanley | $100.00(+44%) | $69.25 | TheFly | |
| Feb 6, 2026 | Morgan Stanley | $78.00(+17%) | $66.64 | TheFly | |
| Jan 27, 2026 | Robert W. Baird | $81.00(+21%) | $67.02 | StreetInsider | |
| Jan 21, 2026 | H.C. Wainwright | $100.00(+45%) | $68.80 | TheFly | |
| Jan 13, 2026 | UBS | $110.00(+62%) | $68.03 | StreetInsider | |
| Jan 13, 2026 | Piper Sandler | $110.00(+67%) | $65.93 | TheFly | |
| Jan 7, 2026 | Morgan Stanley | $81.00(+14%) | $70.81 | TheFly | |
| Jan 7, 2026 | Chardan Capital | $80.00(+13%) | $70.81 | TheFly |
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| Chardan Capital | maintain | Buy | Oct 15, 2026 |
| HC Wainwright & Co. | maintain | Buy | Oct 15, 2026 |
| HC Wainwright & Co. | maintain | Buy | Sep 1, 2026 |
| RBC Capital | maintain | Outperform | Aug 31, 2026 |
| Chardan Capital | maintain | Buy | Aug 31, 2026 |
| HC Wainwright & Co. | maintain | Buy | Aug 6, 2026 |
| B. Riley Securities | maintain | Buy | Jul 30, 2026 |
| HC Wainwright & Co. | maintain | Buy | Jul 27, 2026 |
| Piper Sandler | maintain | Overweight | Jul 23, 2026 |
| Morgan Stanley | maintain | Overweight | Jul 23, 2026 |
| Chardan Capital | maintain | Buy | Jul 22, 2026 |
| JP Morgan | maintain | Overweight | Jul 17, 2026 |
| HC Wainwright & Co. | maintain | Buy | Jul 1, 2026 |
| Chardan Capital | maintain | Buy | Jun 30, 2026 |
| Leerink Partners | maintain | Market Perform | Jun 17, 2026 |
| Bernstein | maintain | Market Perform | May 13, 2026 |
| RBC Capital | maintain | Outperform | May 8, 2026 |
| Morgan Stanley | upgrade | Equal Weight →Overweight | Apr 21, 2026 |
| HC Wainwright & Co. | maintain | Buy | Mar 25, 2026 |
| HC Wainwright & Co. | maintain | Buy | Feb 10, 2026 |
| B. Riley Securities | maintain | Buy | Jan 22, 2026 |
| HC Wainwright & Co. | maintain | Buy | Jan 21, 2026 |
| Piper Sandler | maintain | Overweight | Jan 13, 2026 |
| Morgan Stanley | maintain | Equal Weight | Jan 7, 2026 |
| Chardan Capital | maintain | Buy | Jan 7, 2026 |
Earnings History
| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Aug 4, 2026 | $-1.36 | $-1.28 | $75.3M | $44.2M |
| May 7, 2026 | $-0.93 | $-1.09 | $73.7M | $73.8M |
| Feb 5, 2026 | $0.22 | $0.60 | $264.0M | $213.9M |
| Nov 25, 2025 | $-0.18 | $-0.11 | $256.5M | $175.3M |
| Aug 7, 2025 | $-1.26 | $-0.94 | $27.8M | $154.1M |
| May 12, 2025 | $2.75 | $-0.06 | $542.7M | $116.3M |
| Feb 10, 2025 | $-1.39 | $-0.42 | $2.5M | $19.1M |
| Nov 26, 2024 | $-1.38 | $-1.05 | $3.6M | $55.1M |
News
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today presented results on two of the RNA interference (RNAi) based therapies in its cardiometabolic pipeline at
PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today presented results on two of the RNA interference (RNAi) based therapies in its cardiometabolic pipeline at the American Heart Association (AHA) Scientific Sessions 2026 in Chicago. The presentations included multiple studies of plozasiran in patients with familial chylomicronemia syndrome (FCS) and severe hypertriglyceridemia (sHTG), and interim results from a Phase 1/2a study of investigational ARO-DIMER-PA.
PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has completed a refinancing with funds managed by Sixth Street that lowers its borrowing costs, improves near-term liquidity, extends its debt maturity, and increases financial and operational flexibility. The transaction retires Arrowhead's existing $400 million Sixth Street facility at a $68 million discount to the contractual minimum repayment amount and establishes a new $400 million Si.
PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) announced today that it will present important data at this week's American Heart Association Scientific Sessions in Chicago. AHA 2026 Oral Presentations Date & Time: Saturday, November 7, 3:15 – 4:30 pm CT Session Title: FS.05: Featured Science Session on Novel Lipid Lowering Therapies Location: Learning Studio 2‚ Science and Technology Hall‚ South Hall Title: First-in-Human Trial of a Dual Functional RNAi Mo.
PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that adults in England and Wales who live with a rare metabolic condition called Familial Chylomicronaemia Syndrome (FCS) will have access to a newly licensed new treatment option available on the NHS to reduce extremely high levels of triglycerides (a type of fat) in their bloodstreams, if the response to diet and conventional triglyceride lowering therapies has been inadequate. REDEMPLO® (plozasi.
DBV Technologies (NASDAQ: DBVT - Get Free Report) and Arrowhead Pharmaceuticals (NASDAQ: ARWR - Get Free Report) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, institutional ownership, risk, dividends, earnings, profitability and analyst recommendations. Risk and Volatility DBV Technologies has a beta
Arrowhead Pharmaceuticals, Inc. exceeded expectations with ARO-MAPT phase 1 results, achieving up to 85% CSF tau reduction and validating its subcutaneous CNS siRNA platform. ARWR plans to expand its CNS pipeline, initiating two new ARO-MAPT phase 2 trials and advancing four additional CNS candidates into the clinic by end of 2027. Recent milestones include strong Redemplo phase 3 data, positive ARO-DIMER-PA results, and FDA STAR program entry for Redemplo, supporting a robust long-term growth o…
Arrowhead Pharmaceuticals, Inc. (ARWR) Discusses ARO-MAPT Interim Results and TRiM CNS Delivery Platform in Investigational CNS Pipeline Transcript
Arrowhead Pharmaceuticals NASDAQ: ARWR presented interim Phase I/II data for ARO-MAPT, an investigational small interfering RNA therapy designed to reduce tau protein expression in the central nervous system, alongside initial clinical results for its TRiM CNS delivery platform.
PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced interim results from an ongoing Phase 1/2a study of ARO-MAPT, the company's investigational RNA interference (RNAi) therapeutic being developed as a potential treatment for Alzheimer's disease and other tauopathies. These results represent the first successful clinical validation of a platform to deliver siRNA across the blood-brain barrier and achieve substantial target gene knockdown in the brain.
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that the United States Food and Drug Administration (FDA) has granted plozasiran entry in the Split Real Time Application Review (STAR) pilot program in connection with Arrowhead's upcoming supplemental new drug application (sNDA) for severe hypertriglyceridemia (sHTG). SHTG is a condition that significantly increases the risk of acute pancreatitis, which is associated with repeated hospit…
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR - Get Free Report) shares crossed below its 200-day moving average during trading on Monday. The stock has a 200-day moving average of $75.86 and traded as low as $62.22. Arrowhead Pharmaceuticals shares last traded at $62.35, with a volume of 2,249,374 shares traded. Analyst Upgrades and Downgrades Several research firms
Arrowhead Pharmaceuticals is positioned to challenge Ionis in severe hypertriglyceridemia (sHTG) with plozasiran, leveraging a faster launch via a $215M priority review voucher. ARWR's SHASTA-3 and SHASTA-4 Phase III data show plozasiran achieves 79–81% median triglyceride reductions and favorable safety, with quarterly dosing and no liver fat or thrombocytopenia signals. Current financials reflect partner-driven revenue and a strategic buildout for sHTG; liquidity of ~$1.35B post-voucher suppor…
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced its plan to host an R&D webinar on Wednesday, October 14, 2026, at 11:30 AM PDT that will focus on investigational therapy ARO-MAPT and Arrowhead's central nervous system (CNS) pipeline. The webinar will feature a presentation from Adam Boxer, M.D., Ph.D., Endowed Professor in Memory and Aging in the Department of Neurology at the University of California, San Francisco (UCSF), where he di…
Arrowhead Pharmaceuticals NASDAQ: ARWR executives outlined early clinical data for its RNA interference dimer program, progress in the launch of plozasiran and plans for central nervous system and metabolic disease candidates during the Morgan Stanley Global Healthcare Conference. Get ARWR alerts:Sign UpEarly Dimer Data Points to Dual-Target Approach Chief Executive Officer Chris Anzalone said the company's ARO-DIMER-PA candidate represented the first demonstration of knockdown of two genes with…
Arrowhead Pharmaceuticals NASDAQ: ARWR is expanding its commercial and clinical footprint around RNA interference therapies, with its recently launched triglyceride-lowering treatment REDEMPLO and several pipeline programs targeting cardiometabolic disease, obesity and central nervous system disorders.
Arrowhead Pharmaceuticals, Inc. (ARWR) Presents at H.C. Wainwright 28th Annual Global Investment Conference Transcript
Arrowhead Pharmaceuticals, Inc. (ARWR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
[url="]Arrowhead Pharmaceuticals, Inc.[/url] (NASDAQ: ARWR) today announced interim topline data from a Phase 1/2a clinical trial of ARO-DIMER-PA, the company's
PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced interim topline data from a Phase 1/2a clinical trial of ARO-DIMER-PA, the company's first investigational RNA interference (RNAi) therapeutic dimer being developed as a potential treatment for atherosclerotic cardiovascular disease (ASCVD) due to mixed hyperlipidemia. ARO-DIMER-PA is designed to silence expression of both proprotein convertase subtilisin kexin 9 (PCSK9) and apolipoprotein C3 (APOC.